XLO Q2 2024 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

XLOXilio Therapeutics, Inc.

$28M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M100.0% margin

Operating Income

-$15M-623.8% margin

Net Income

-$14M-590.8% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$90M

Total Liabilities

$56M

Stockholders' Equity

$33M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$2M	-$492,000	+579.1%
Operating Income	-$15M	-$20M	+26.9%
Net Income	-$14M	-$19M	+28.1%